Viking Therapeutics (VKTX) Tops Q2 EPS by 13c

Viking Therapeutics (NASDAQ: VKTX) reported Q2 EPS of ($1.10), $0.13 better than the analyst estimate of ($1.23).

For earnings history and earnings-related data on Viking Therapeutics (VKTX) click here.

You May Also Be Interested In

• Bernstein SocGen Group Reiterates Outperform Rating on Zydus Lifesciences (ZYDUSLIF:IN)
• Barclays Upgrades ASOS Plc. (ASC:LN) (ASOMY) to Equalweight
• Hindustan Unilever Ltd (HUVR:IN) PT Lowered to INR2,115 at Kotak